NEW YORK (GenomeWeb) – Roche's Ventana Medical Systems today announced a deal with ImmunoGen to develop an immunohistochemistry-based companion diagnostic test for the oncology therapeutic firm's product candidates.

The companies have initially developed a test for folate receptor alpha, FRa, also known as folate receptor 1, or FOL1. The test is being used in early trials for ImmunoGen's FRa-targeting antibody conjugate IMGN853. Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.